Skip to content

ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521478-32-00
Acronym
APHP230825
Enrollment
110
Registered
2025-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PEDIATRIC ACUTE MYOCARDITIS

Brief summary

Proportion of children with recovered left ventricle ejection fraction (LVEF ≥ 50%) measured by echocardiography at 3 days after treatment initiation. Patients who die within the first 3 days after treatment initiation or patients who still require ECMO at 3 days after treatment initiation will be considered as a failure.

Detailed description

Proportion of children with recovered left ventricle ejection fraction (LVEF ≥ 50%) measured by echocardiography at 7 and 28 days after treatment initiation. Patients who die or undergo heart transplant within the first 7 and 28 days after treatment initiation respectively will be considered as a failure (i.e, LVEF < 50%). Patients who still require ECMO at 7 and 28 days after treatment initiation respectively will also be considered as failure (i.e., LVEF < 50%)., Time to recovery of normal left ventricular ejection fraction (LVEF ≥ 50%) within the first 3 days after treatment initiation 3- Proportion of children requiring ECMO within the first 3 days after treatment initiation, Proportion of children requiring ECMO within the first 3 days after treatment initiation, Proportion of children who undergo heart transplant within 6 months after treatment initiation, Time to all-cause death within 6 months after treatment initiation, Time to cardiovascular-related death within 6 months after treatment initiation, Proportion of children with drug-related side effects (hypersensitivity, neutropenia, drug-related liver enzymes elevation…), a- o NT proBNP at inclusion and at 24 hours, 48 hours, 72 hours following treatment initiation o Troponin T at inclusion and at 24 hours, 48 hours, 72 hours following treatment initiation o Proportion of children with ventricular tachycardia assessed by EKG at inclusion and at 24 hours, 48 hours, 72 hours following treatment initiation b- o NT proBNP at 7 days following treatment initiation o Troponin T at 7 days following treatment initiation o Proportion of children with ventricular tachyca

Interventions

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Proportion of children with recovered left ventricle ejection fraction (LVEF ≥ 50%) measured by echocardiography at 3 days after treatment initiation. Patients who die within the first 3 days after treatment initiation or patients who still require ECMO at 3 days after treatment initiation will be considered as a failure.

Secondary

MeasureTime frame
Proportion of children with recovered left ventricle ejection fraction (LVEF ≥ 50%) measured by echocardiography at 7 and 28 days after treatment initiation. Patients who die or undergo heart transplant within the first 7 and 28 days after treatment initiation respectively will be considered as a failure (i.e, LVEF < 50%). Patients who still require ECMO at 7 and 28 days after treatment initiation respectively will also be considered as failure (i.e., LVEF < 50%)., Time to recovery of normal left ventricular ejection fraction (LVEF ≥ 50%) within the first 3 days after treatment initiation 3- Proportion of children requiring ECMO within the first 3 days after treatment initiation, Proportion of children requiring ECMO within the first 3 days after treatment initiation, Proportion of children who undergo heart transplant within 6 months after treatment initiation, Time to all-cause death within 6 months after treatment initiation, Time to cardiovascular-related death within 6 months afte

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026